🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In 2010, the NHS was rated the fairest, most efficient & cost-effective healthcare system in the world. The Tories spent 14 years buggering it up. We don't need "reform", FFS, Labour. We need the NHS put back to its unbuggered-up state. Which means un-privatise it and fund it

Tomorrow morning at #ESMO24, we will hear new results from the two final comparisons of the #STAMPEDEtrial in #ProstateCancer: ➡️tE2 M0 results ➡️Metformin M1 results. These results are complementary but not overlapping. More results will follow, providing a fuller picture.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial - The Lancet thelancet.com/journals/lance…

Dr Grist AttardLab at #ESMO2024 Decipher by Veracyte DECIPHER prognostic for OS in mHSPC but most importantly predictive for efficacy of docetaxel. Not predictive for Abi effect.

Why is climate change a health crisis? Find out more about your specialties and what you can do to tackle climate change TOMORROW, 17th September. #WorldPatientSafetyDay2024 #OurHealthOurPlanet Join the launch: eventbrite.co.uk/e/our-health-o… Centre for Sustainable Healthcare UK Health Alliance on Climate Change

Ruth Langley shows the first of 2 #STAMPEDE outputs this morning. First tE2 PATCH / Stampede hits non inferiority (with ⬆️QOL) vs ADT in M0. A new therapy option!

Presented at #ESMO24 and published simultaneously The Lancet Oncology: thelancet.com/journals/lanon… The randomised ph2 UpFrontPSMA study: Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive #prostatecancer

Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024

There is something pretty grotesque about fast tracking assisted dying legislation while doing nothing about social care costs

During earlier debates on euthanasia, Dominic Lawson & George Pitcher brilliantly argued for “care not kill.”Movingly,Alison Davis said she had been given 25 years of extra life which would have been denied if her wish to die had been granted:missing “the best years of my life.”

Check out this great discussion between Oliver Sartor and Alicia Morgans, MD, MPH > bit.ly/47ojcyV, written coverage from #ESMO24 > bit.ly/3Xqx3A3

I deeply sympathise with the arguments for assisted dying. But from an economic POV, the incentives for the state (and for potentially unscrupulous individuals) all line up in exactly the wrong direction and I'm afraid I don't trust in our ability to safeguard the vulnerable.

Every day 320 people who need specialist palliative care can't access that care.... THAT is the real priority. #AssistedDying comes last in the public's list of priorities

#ProstateCancer efficacy results from a randomized phase 3 evaluation of transdermal estradiol vs LHRH agonists for androgen suppression in M0 prostate cancer. Presented by Ruth Langley, PhD MRC Clinical Trials Unit at UCL. #ESMO24 written coverage by Zach Klaassen > bit.ly/4d6XNLN

Third #Stampede presentation by silke gillessen. Metformin has weak effect on OS with possible interaction with disease volume. Significant positive effects on metabolic outcomes MRC Clinical Trials Unit at UCL The ICR

Transdermal oestradiol patches are as good as standard hormone therapy injections at treating #ProstateCancer that has not spread. This could offer more choice for patients. Ruth Langley presented new results from the PATCH & STAMPEDE trials at #ESMO24🧵 bit.ly/4e6n8GV

Second #Stampede presentation today silke gillessen on metformin in M1HSPC. Borderline OS gain, ?more in HV disease. Significant metabolic gains all pts MRC Clinical Trials Unit at UCL The ICR

Neeraj Agarwal, MD, FASCO silke gillessen ESMO - Eur. Oncology UroToday.com PCF Science OncoAlert Cancer Research UK Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Petros Grivas Shilpa Gupta Yüksel Ürün Umang Swami GU Cancer Research Program @HuntsmanCancer Bogdana Schmidt MD, MPH Arun Azad Ravindran Kanesvaran But there were favorable metabolic effects, which could be impactful in overall health and longevity

Metformin in prostate cancer in a controlled trial with overall survival as the endpoint, and with metabolic secondary endpoints.

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA) out on The Lancet Oncology and presented at #ESMO24 thelancet.com/journals/lanon… The UpFrontPSMA phase 2 trial evaluated the use of Lutetium-177